Literature DB >> 34933043

Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.

Noopur Bhatnagar1, Ki-Hye Kim2, Jeeva Subbiah1, Bo Ryoung Park1, Eun-Ju Ko3, Baik-Lin Seong4, Sang-Moo Kang5.   

Abstract

Vaccination against influenza viruses suffers from low efficacy in conferring homologous and cross-protection, particularly in older adults. Here, we compared the effects of three different adjuvant types (QS-21+MPL, CpG+MPL and bacterial cell wall CWS) on enhancing the immunogenicity and homologous and heterosubtypic protection of influenza vaccination in young adult and aged mouse models. A combination of saponin QS-21 and monophosphoryl lipid A (QS-21+MPL) was most effective in inducing T helper type 1 (Th1) T cell and cross-reactive IgG as well as hemagglutination inhibiting antibody responses to influenza vaccination. Both combination adjuvants (QS-21+MPL and CpG+MPL) exhibited high potency by preventing weight loss and reducing viral loads and enhanced homologous and cross-protection by influenza vaccination in adult and aged mouse models. Bacillus Calmette-Guerin cell-wall skeleton (CWS) displayed substantial adjuvant effects on immune responses to influenza vaccination but lower adjuvant efficacy in inducing Th1 IgG responses, cross-protection in adult mice, and in conferring homologous protection in aged mice. This study has significance in comparing the effects of potent adjuvants on enhancing humoral and cellular immune responses to influenza virus vaccination, inducing homologous and cross-protection in adult and aged populations.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvant; Cross-protection; Influenza virus; Split vaccine

Mesh:

Substances:

Year:  2021        PMID: 34933043      PMCID: PMC8801234          DOI: 10.1016/j.antiviral.2021.105229

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  37 in total

1.  MPL and CpG combination adjuvants promote homologous and heterosubtypic cross protection of inactivated split influenza virus vaccine.

Authors:  Eun-Ju Ko; Youri Lee; Young-Tae Lee; Yu-Jin Kim; Ki-Hye Kim; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2018-06-06       Impact factor: 5.970

2.  Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity.

Authors:  K Oishi; N L Koles; G Guelde; M Pollack
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

3.  Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein.

Authors:  Ze Chen; Tomoki Yoshikawa; Shin-Etsu Kadowaki; Yukari Hagiwara; Kazutoshi Matsuo; Hideki Asanuma; Chikara Aizawa; Takeshi Kurata; Shin-Ichi Tamura
Journal:  J Gen Virol       Date:  1999-10       Impact factor: 3.891

4.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

Authors:  T L Stevens; A Bossie; V M Sanders; R Fernandez-Botran; R L Coffman; T R Mosmann; E S Vitetta
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

5.  Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.

Authors:  Young-Tae Lee; Eun-Ju Ko; Youri Lee; Ki-Hye Kim; Min-Chul Kim; Yu-Na Lee; Sang-Moo Kang
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

6.  Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.

Authors:  Margherita Coccia; Catherine Collignon; Caroline Hervé; Aurélie Chalon; Iain Welsby; Sophie Detienne; Mary J van Helden; Sheetij Dutta; Christopher J Genito; Norman C Waters; Katrijn Van Deun; Age K Smilde; Robert A van den Berg; David Franco; Patricia Bourguignon; Sandra Morel; Nathalie Garçon; Bart N Lambrecht; Stanislas Goriely; Robbert van der Most; Arnaud M Didierlaurent
Journal:  NPJ Vaccines       Date:  2017-09-08       Impact factor: 7.344

7.  BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).

Authors:  Luis E Escobar; Alvaro Molina-Cruz; Carolina Barillas-Mury
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-09       Impact factor: 11.205

8.  BCG Cell Wall Skeleton As a Vaccine Adjuvant Protects Both Infant and Old-Aged Mice from Influenza Virus Infection.

Authors:  Ki-Hye Kim; Young-Tae Lee; Yoonsuh Park; Eun-Ju Ko; Yu-Jin Jung; Yu-Jin Kim; Eun-Kyeong Jo; Sang-Moo Kang
Journal:  Biomedicines       Date:  2021-05-05

9.  Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites.

Authors: 
Journal:  PLoS Med       Date:  2014-07-29       Impact factor: 11.069

10.  Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Authors:  Olivier Van Der Meeren; Mark Hatherill; Videlis Nduba; Robert J Wilkinson; Monde Muyoyeta; Elana Van Brakel; Helen M Ayles; German Henostroza; Friedrich Thienemann; Thomas J Scriba; Andreas Diacon; Gretta L Blatner; Marie-Ange Demoitié; Michele Tameris; Mookho Malahleha; James C Innes; Elizabeth Hellström; Neil Martinson; Tina Singh; Elaine J Akite; Aisha Khatoon Azam; Anne Bollaerts; Ann M Ginsberg; Thomas G Evans; Paul Gillard; Dereck R Tait
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.